Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

<p>Abstract</p> <p>Because of its low toxicity, low-dose (LD) chemotherapy is ideally suited for combination with antiangiogenic drugs. We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its interactions with...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Leiby Benjamin, Alagkiozidis Ioannis, Zhang Lin, Mohamed-Hadley Alisha, Krafty Robert T, Holtz David O, Guo Wensheng, Gimotty Phyllis A, Coukos George
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2008-01-01
Serie:	Journal of Translational Medicine
Accesso online:	http://www.translational-medicine.com/content/6/1/2
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!